MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Estimates By $0.16 EPS

MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Wednesday. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.16), FiscalAI reports.

MoonLake Immunotherapeutics Trading Down 1.2%

NASDAQ MLTX traded down $0.14 on Wednesday, reaching $11.56. The company had a trading volume of 956,691 shares, compared to its average volume of 1,534,635. The stock’s 50 day moving average is $12.36 and its 200-day moving average is $16.41. The stock has a market cap of $983.79 million, a price-to-earnings ratio of -3.01 and a beta of 1.14. The company has a quick ratio of 12.56, a current ratio of 12.56 and a debt-to-equity ratio of 0.23. MoonLake Immunotherapeutics has a 52 week low of $9.46 and a 52 week high of $23.29.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, September 16th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of MoonLake Immunotherapeutics in a research note on Monday, October 5th. Wall Street Zen downgraded shares of MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, September 27th. Finally, Weiss Ratings upgraded shares of MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.50.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company is advancing medicines designed to address conditions in which the immune system contributes to chronic inflammation and tissue damage.

Its lead product candidate is sonelokimab, an investigational Nanobody-based therapy designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease.